Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole and Rifampicin on Jaktinib PK
NCT06246695Phase 1Completed
- Sponsor
- Zelgen
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of jaktinib in myelofibrosis (MF) (2 arms), sponsored by Zelgen. Primary endpoints: Maximum Plasma Concentration up to 32 Days, Area Under the Curve up to 32 Days and 1 more. Started Oct 2021; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06246695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246695.